Amedisys (AMED) Tops Q3 EPS by 18c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Amedisys (AMED) PT Raised to $126 at RBC Capital
October 31, 2018 6:59 AM EDTRBC Capital analyst Frank Morgan raised the price target on Amedisys (NASDAQ: AMED) to $126.00 (from $115.00) while maintaining an Outperform rating.
Morgan noted a strong Q3, with momentum in 2019.
... More


